The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 3×
“served region located at the binding site for isocitrate [14].”
BackgroundIDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · cited 2×
“This inactivation is due to impaired substrate affinity, and moreover, IDH1 mutations exert a dominant negative effect rendering heterodimers inactive as well [22].”
BackgroundAnalysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036 · cited 10×
“5% for O III comparing to 67% [1], 86% [21], 75% [17] and 60% [8].”
BackgroundResultInfluentialSelf-citationIDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027 · cited 9×
“5% for O III comparing to 67% [1], 86% [21], 75% [17] and 60% [8].”
BackgroundResultInfluentialWick, W., Hartmann, C., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., Sabel, M. C., Koeppen, S., Ketter, R., Meyermann, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6497 · Cited by 809
Self-citationIDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
Ichimura, K., Pearson, D. M., Kocialkowski, S., Bäcklund, L. M., Chan, R., Jones, D. T. W., & Collins, V. P. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-025 · Cited by 595
Khanna, C., Anderson, P. M., Hasz, D. E., Katsanis, E., Neville, M., & Klausner, J. S. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970401)79:7 · Cited by 561
Expanding chemical biology of 2-oxoglutarate oxygenases
Loenarz, C., & Schofield, C. J. (2008) · Nature Chemical Biology · doi:10.1038/nchembio0308-152 · Cited by 497
Cited by
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
“This is in contrast to the data reported for gliomas in which less than 5% of IDH mutations were in IDH2 (Hartmann et al., 2009; Yan et al., 2009).”
ResultEpidemiologic and Molecular Prognostic Review of Glioblastoma
Thakkar, J. P., Dolecek, T. A., Horbinski, C., Ostrom, Q. T., Lightner, D. D., Barnholtz-Sloan, J. S., & Villano, J. L. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0275 · Cited by 1,390
Mutational landscape and clonal architecture in grade II and III gliomas
Suzuki, H., Aoki, K., Chiba, K., Sato, Y., Shiozawa, Y., Shiraishi, Y., Shimamura, T., Niida, A., Motomura, K., Ohka, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3273 · Cited by 831
Hartmann, C., Hentschel, B., Wick, W., Capper, D., Felsberg, J., Simon, M., Westphal, M., Schackert, G., Meyermann, R., Pietsch, T., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0781-z · Cited by 829
Self-citationVorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304194 · Cited by 814
Self-citationPaschka, P., Schlenk, R. F., Gaidzik, V. I., Habdank, M., Krönke, J., Bullinger, L., Späth, D., Kayser, S., Zucknick, M., Götze, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3762 · Cited by 801
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma
Huse, J. T., & Holland, E. C. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2818 · Cited by 763
Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736
Glioblastoma: pathology, molecular mechanisms and markers
Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G., & von Deimling, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1432-1 · Cited by 735
Self-citationNavigating metabolic pathways to enhance antitumour immunity and immunotherapy
Li, X., Wenes, M., Romero, P., Huang, S. C.-C., Fendt, S.-M., & Ho, P.-C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0203-7 · Cited by 733
Genetic and molecular epidemiology of adult diffuse glioma
Molinaro, A. M., Taylor, J. W., Wiencke, J. K., & Wrensch, M. R. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0220-2 · Cited by 709
IDH1 and IDH2 mutations in gliomas
Cohen, A. L., Holmen, S. L., & Colman, H. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0345-4 · Cited by 629
Frequent ATRX , CIC , FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Jiao, Y., Killela, P. J., Reitman, Z. J., Rasheed, B. A., Heaphy, C. M., de Wilde, R. F., Rodriguez, F. J., Rosemberg, S., Oba-Shinjo, S. M., Nagahashi Marie, S. K., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.588 · Cited by 584
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Losman, J.-A., & Kaelin, W. G. (2013) · Genes & Development · doi:10.1101/gad.217406.113 · Cited by 570
Emerging insights into the molecular and cellular basis of glioblastoma
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012) · Genes & Development · doi:10.1101/gad.187922.112 · Cited by 565
Reitman, Z. J., & Yan, H. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq187 · Cited by 562
Pansuriya, T. C., van Eijk, R., d'Adamo, P., van Ruler, M. A. J. H., Kuijjer, M. L., Oosting, J., Cleton-Jansen, A.-M., van Oosterwijk, J. G., Verbeke, S. L. J., Meijer, D., et al. (2011) · Nature Genetics · doi:10.1038/ng.1004 · Cited by 559
Glioma epigenetics: From subclassification to novel treatment options
Gusyatiner, O., & Hegi, M. E. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.010 · Cited by 541
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
Houillier, C., Wang, X., Kaloshi, G., Mokhtari, K., Guillevin, R., Laffaire, J., Paris, S., Boisselier, B., Idbaih, A., Laigle-Donadey, F., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f96282 · Cited by 535
Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.69 · Cited by 534
Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors
Capper, D., Weißert, S., Balss, J., Habel, A., Meyer, J., Jäger, D., Ackermann, U., Tessmer, C., Korshunov, A., Zentgraf, H., et al. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00352.x · Cited by 526
Self-citationBCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1
Tönjes, M., Barbus, S., Park, Y. J., Wang, W., Schlotter, M., Lindroth, A. M., Pleier, S. V., Bai, A. H. C., Karra, D., Piro, R. M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3217 · Cited by 486
Self-citationIntegrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas
Ryall, S., Zapotocky, M., Fukuoka, K., Nobre, L., Guerreiro Stucklin, A., Bennett, J., Siddaway, R., Li, C., Pajovic, S., Arnoldo, A., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.011 · Cited by 474
Beiko, J., Suki, D., Hess, K. R., Fox, B. D., Cheung, V., Cabral, M., Shonka, N., Gilbert, M. R., Sawaya, R., Prabhu, S. S., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not159 · Cited by 456
IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives
Yang, H., Ye, D., Guan, K.-L., & Xiong, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1773 · Cited by 458
Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion
Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.006 · Cited by 433
Reuss, D. E., Sahm, F., Schrimpf, D., Wiestler, B., Capper, D., Koelsche, C., Schweizer, L., Korshunov, A., Jones, D. T. W., Hovestadt, V., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1370-3 · Cited by 449
Self-citationProfiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
Reitman, Z. J., Jin, G., Karoly, E. D., Spasojevic, I., Yang, J., Kinzler, K. W., He, Y., Bigner, D. D., Vogelstein, B., & Yan, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019393108 · Cited by 449
Glioblastoma targeted therapy: updated approaches from recent biological insights
Touat, M., Idbaih, A., Sanson, M., & Ligon, K. L. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx106 · Cited by 441
Monoclonal antibody specific for IDH1 R132H mutation
Capper, D., Zentgraf, H., Balss, J., Hartmann, C., & von Deimling, A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0595-z · Cited by 436
Self-citationLai, A., Kharbanda, S., Pope, W. B., Tran, A., Solis, O. E., Peale, F., Forrest, W. F., Pujara, K., Carrillo, J. A., Pandita, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8715 · Cited by 433
Oncometabolites: linking altered metabolism with cancer
Yang, M., Soga, T., & Pollard, P. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67228 · Cited by 422
The implications of IDH mutations for cancer development and therapy
Pirozzi, C. J., & Yan, H. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00521-0 · Cited by 382
van den Bent, M. J., Dubbink, H. J., Marie, Y., Brandes, A. A., Taphoorn, M. J. B., Wesseling, P., Frenay, M., Tijssen, C. C., Lacombe, D., Idbaih, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2902 · Cited by 381
Self-citationIDH mutations in glioma and acute myeloid leukemia
Dang, L., Jin, S., & Su, S. M. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.07.002 · Cited by 370
The Significance of Mitochondrial Dysfunction in Cancer
Luo, Y., Ma, J., & Lu, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165598 · Cited by 362
Pediatric low-grade glioma in the era of molecular diagnostics
Ryall, S., Tabori, U., & Hawkins, C. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00902-z · Cited by 351
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas
Dougherty, M. J., Santi, M., Brose, M. S., Ma, C., Resnick, A. C., Sievert, A. J., Storm, P. B., & Biegel, J. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq007 · Cited by 324
The 2016 World Health Organization classification of tumours of the central nervous system
Villa, C., Miquel, C., Mosses, D., Bernier, M., & Di Stefano, A. L. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.04.015 · Cited by 319
Pope, W. B., Prins, R. M., Albert Thomas, M., Nagarajan, R., Yen, K. E., Bittinger, M. A., Salamon, N., Chou, A. P., Yong, W. H., Soto, H., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0737-8 · Cited by 318
“IDH1 mutations have recently been found to be associated with a distinct gene expression profile (in particular, the ‘‘proneural’’ subset of glioblastomas) [7, 8] and are considered to be an independent prognostic indicator in these patients [7, 9, 10].”
Tefferi, A., Lasho, T. L., Abdel-Wahab, O., Guglielmelli, P., Patel, J., Caramazza, D., Pieri, L., Finke, C. M., Kilpivaara, O., Wadleigh, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.113 · Cited by 318
Kickingereder, P., Sahm, F., Radbruch, A., Wick, W., Heiland, S., Deimling, A. V., Bendszus, M., & Wiestler, B. (2015) · Scientific Reports · doi:10.1038/srep16238 · Cited by 316
Self-citationWeller, M., Weber, R. G., Willscher, E., Riehmer, V., Hentschel, B., Kreuz, M., Felsberg, J., Beyer, U., Löffler-Wirth, H., Kaulich, K., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1409-0 · Cited by 312
Self-citationZbinden, M., Duquet, A., Lorente‐Trigos, A., Ngwabyt, S., Borges, I., & Ruiz i Altaba, A. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.137 · Cited by 309
Prognostic relevance of genetic alterations in diffuse lower-grade gliomas
Aoki, K., Nakamura, H., Suzuki, H., Matsuo, K., Kataoka, K., Shimamura, T., Motomura, K., Ohka, F., Shiina, S., Yamamoto, T., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox132 · Cited by 307
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system
Koelsche, C., Sahm, F., Capper, D., Reuss, D., Sturm, D., Jones, D. T. W., Kool, M., Northcott, P. A., Wiestler, B., Böhmer, K., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1195-5 · Cited by 303
Self-citationBleeker, F. E., Atai, N. A., Lamba, S., Jonker, A., Rijkeboer, D., Bosch, K. S., Tigchelaar, W., Troost, D., Vandertop, W. P., Bardelli, A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0645-6 · Cited by 302
Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications
Malta, T. M., de Souza, C. F., Sabedot, T. S., Silva, T. C., Mosella, M. S., Kalkanis, S. N., Snyder, J., Castro, A. V. B., & Noushmehr, H. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox183 · Cited by 302
Cancer-associated IDH mutations: biomarker and therapeutic opportunities
Yen, K. E., Bittinger, M. A., Su, S. M., & Fantin, V. R. (2010) · Oncogene · doi:10.1038/onc.2010.444 · Cited by 296
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma
SongTao, Q., Lei, Y., Si, G., YanQing, D., HuiXia, H., XueLin, Z., LanXiao, W., & Fei, Y. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2011.02134.x · Cited by 294
Low-grade gliomas in adults: A review
Sanai, N., Chang, S., & Berger, M. S. (2011) · Journal of Neurosurgery · doi:10.3171/2011.7.jns101238 · Cited by 291
Metellus, P., Coulibaly, B., Colin, C., de Paula, A. M., Vasiljevic, A., Taieb, D., Barlier, A., Boisselier, B., Mokhtari, K., Wang, X. W., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0777-8 · Cited by 289
Molecular diagnostics of gliomas: state of the art
Riemenschneider, M. J., Jeuken, J. W. M., Wesseling, P., & Reifenberger, G. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0736-4 · Cited by 283
Self-citationIsocitrate dehydrogenase mutations in gliomas
Waitkus, M. S., Diplas, B. H., & Yan, H. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov136 · Cited by 282
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities
Reuss, D. E., Kratz, A., Sahm, F., Capper, D., Schrimpf, D., Koelsche, C., Hovestadt, V., Bewerunge-Hudler, M., Jones, D. T. W., Schittenhelm, J., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1454-8 · Cited by 280
Self-citationWhole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
Kannan, K., Inagaki, A., Silber, J., Gorovets, D., Zhang, J., Kastenhuber, E. R., Heguy, A., Petrini, J. H., Chan, T. A., & Huse, J. T. (2012) · Oncotarget · doi:10.18632/oncotarget.689 · Cited by 278
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers
Jansen, M., Yip, S., & Louis, D. N. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70105-8 · Cited by 275
Sahm, F., Reuss, D., Koelsche, C., Capper, D., Schittenhelm, J., Heim, S., Jones, D. T. W., Pfister, S. M., Herold-Mende, C., Wick, W., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1326-7 · Cited by 272
Self-citationMultimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas
Zhang, B., Chang, K., Ramkissoon, S., Tanguturi, S., Bi, W. L., Reardon, D. A., Ligon, K. L., Alexander, B. M., Wen, P. Y., & Huang, R. Y. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now121 · Cited by 263
Using the molecular classification of glioblastoma to inform personalized treatment
Olar, A., & Aldape, K. D. (2014) · The Journal of Pathology · doi:10.1002/path.4282 · Cited by 261
Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management
Wang, Y., & Jiang, T. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.12.024 · Cited by 260
Metabolic adaptation in hypoxia and cancer
Paredes, F., Williams, H. C., & San Martin, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.020 · Cited by 259
Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery
Santagata, S., Eberlin, L. S., Norton, I., Calligaris, D., Feldman, D. R., Ide, J. L., Liu, X., Wiley, J. S., Vestal, M. L., Ramkissoon, S. H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404724111 · Cited by 258
Long‐Term Epilepsy‐Associated Tumors
Thom, M., Blümcke, I., & Aronica, E. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00582.x · Cited by 231
Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma?
Kloosterhof, N. K., Bralten, L. B., Dubbink, H. J., French, P. J., & van den Bent, M. J. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70053-x · Cited by 222
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
de Botton, S., Mondesir, J., Willekens, C., & Touat, M. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s70716 · Cited by 220
Characterizing DNA methylation alterations from The Cancer Genome Atlas
Weisenberger, D. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69740 · Cited by 200
“These mutations occur at a low frequency and are mutually exclusive with IDH1 mutations (42, 43).”
Wakimoto, H., Tanaka, S., Curry, W. T., Loebel, F., Zhao, D., Tateishi, K., Chen, J., Klofas, L. K., Lelic, N., Kim, J. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3052 · Cited by 190
“All 8 xenograft-forming tumors and 10 of 12 non-xenograft-forming tumors harbored the IDH1 R132H variant, which accounts for ~90% of the IDH1 mutations in gliomas (2, 12, 36), and the remaining two non-xenograft-forming gliomas harbored IDH1 R132C.”
2-Hydroxyglutarate in Cancer Cells
Ježek, P. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7902 · Cited by 130
Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype
Wu, Y., Fletcher, M., Gu, Z., Wang, Q., Costa, B., Bertoni, A., Man, K.-H., Schlotter, M., Felsberg, J., Mangei, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20225-w · Cited by 101
Self-citationNatsume, A., Arakawa, Y., Narita, Y., Sugiyama, K., Hata, N., Muragaki, Y., Shinojima, N., Kumabe, T., Saito, R., Motomura, K., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac155 · Cited by 93
Jaber, M., Ewelt, C., Wölfer, J., Brokinkel, B., Thomas, C., Hasselblatt, M., Grauer, O., & Stummer, W. (2019) · Neurosurgery · doi:10.1093/neuros/nyy365 · Cited by 66
Goze, C., Blonski, M., Le Maistre, G., Bauchet, L., Dezamis, E., Page, P., Varlet, P., Capelle, L., Devaux, B., Taillandier, L., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou085 · Cited by 56
Baumgarten, P., Harter, P. N., Tönjes, M., Capper, D., Blank, A. ‐., Sahm, F., von Deimling, A., Kolluru, V., Schwamb, B., Rabenhorst, U., et al. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12088 · Cited by 53
Self-citationZhao, J., Li, J.-B., Wang, J.-Y., Wang, Y.-L., Liu, D.-W., Li, X.-B., Song, Y.-K., Tian, Y.-S., Yan, X., Li, Z.-H., et al. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.04.011 · Cited by 41
“The most prominent change is that the new edition incorporates the status of isocitrate dehydrogenase (IDH) into glioma diagnosis, with the majority of IDH mutations being IDH-1 positive (Hartmann et al., 2009).”
Background
Metadata
- Authors
- Hartmann, C., Meyer, J., Balss, J., Capper, D., Mueller, W., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., Weller, M., Herold-Mende, C., Unterberg, A., Jeuken, J. W. M., Wesseling, P., Reifenberger, G., & von Deimling, A.
- Venue
- Acta Neuropathologica
- Published
- 2009-06-25
- Volume
- 118
- Issue
- 4
- Pages
- 469-474
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2168784615
- Cited by
- 1,163
- References
- 21
- FWCI
- 37.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.